Management of Transplant-Ineligible Multiple Myeloma

EP. 1: Goals of Therapy for Transplant-Ineligible MM

ByRobert Z. Orlowski, MD, PhD,Larry Anderson, MD, PhD,Caitlin Costello, MD,Jeffrey V. Matous, MD

September 8th 2021

Kicking off a discussion regarding treatment approaches for transplant-ineligible multiple myeloma, a panel of hematologist-oncologists highlights goals of therapy for newly diagnosed patients.

EP. 2: Strategies to Monitor Multiple Myeloma

ByRobert Z. Orlowski, MD, PhD,Larry Anderson, MD, PhD,Caitlin Costello, MD,Jeffrey V. Matous, MD

September 10th 2021

Different markers and tests that are used to monitor disease status and treatment response in patients with multiple myeloma.

EP. 3: Frequency of Measuring Treatment Response in MM

ByRobert Z. Orlowski, MD, PhD,Larry Anderson, MD, PhD,Caitlin Costello, MD,Jeffrey V. Matous, MD

September 15th 2021

Recommendations for measuring treatment response in patients with multiple myeloma utilizing tests such as MRD assessments.

EP. 4: MRD Testing in Multiple Myeloma

ByRobert Z. Orlowski, MD, PhD,Larry Anderson, MD, PhD,Caitlin Costello, MD,Jeffrey V. Matous, MD

September 17th 2021

Current techniques used to assess MRD status in patients with multiple myeloma, and advice to hematologist-oncologists who are considering flow cytometry or molecular testing.

EP. 5: Managing Adequate/Inadequate Treatment Response in MM

ByRobert Z. Orlowski, MD, PhD,Larry Anderson, MD, PhD,Caitlin Costello, MD,Jeffrey V. Matous, MD

September 22nd 2021

Recommended next steps regarding treatment for patients with transplant-ineligible multiple myeloma based on prior responses to therapy.

EP. 6: Managing A Case of Newly-Diagnosed Transplant-Ineligible MM

ByRobert Z. Orlowski, MD, PhD,Larry Anderson, MD, PhD,Caitlin Costello, MD,Jeffrey V. Matous, MD

September 24th 2021

A panel of hematologist-oncologists comment on how they would treat a 74-year-old patient with newly diagnosed transplant-ineligible multiple myeloma.

EP. 7: Triplet Vs Doublet Therapy for Transplant-Ineligible MM

ByRobert Z. Orlowski, MD, PhD,Larry Anderson, MD, PhD,Caitlin Costello, MD,Jeffrey V. Matous, MD

September 29th 2021

Scenarios for which a doublet regimen may be recommended over a triplet therapy for the management of newly diagnosed transplant-ineligible multiple myeloma.

EP. 8: Maintenance Therapy for Transplant-Ineligible MM

ByRobert Z. Orlowski, MD, PhD,Larry Anderson, MD, PhD,Caitlin Costello, MD,Jeffrey V. Matous, MD

October 1st 2021

Take-home points from the MAIA trial of daratumumab plus lenalidomide and dexamethasone as therapy for patients with newly diagnosed transplant-ineligible multiple myeloma, and recommendations regarding maintenance therapy following the use of a triplet regimen.

EP. 9: Transplant-Ineligible MM: Treating to Progression

ByRobert Z. Orlowski, MD, PhD,Larry Anderson, MD, PhD,Caitlin Costello, MD,Jeffrey V. Matous, MD

October 6th 2021

The rationale behind treating patients with newly diagnosed transplant-ineligible multiple myeloma (MM) until disease progression rather than stopping therapy at a designated point in time.

EP. 10: Transplant-Ineligible MM: Reinitiating Therapy

ByRobert Z. Orlowski, MD, PhD,Larry Anderson, MD, PhD,Caitlin Costello, MD,Jeffrey V. Matous, MD

October 8th 2021

Triggers that may lead a hematologist/oncologist to consider reinstituting therapy for a patient with transplant-ineligible multiple myeloma (MM) who received prior therapy but was not treated to progression.

EP. 11: Counseling Patients With MM About Treatment Duration

ByRobert Z. Orlowski, MD, PhD,Larry Anderson, MD, PhD,Caitlin Costello, MD,Jeffrey V. Matous, MD

October 13th 2021

Recommendations when talking with patients with transplant-ineligible multiple myeloma (MM) who request to stop receiving treatment.

EP. 12: Transplant-Ineligible MM: Navigating Treatment Challenges

ByRobert Z. Orlowski, MD, PhD,Larry Anderson, MD, PhD,Caitlin Costello, MD,Jeffrey V. Matous, MD

October 15th 2021

A panel of hematologists/oncologists conclude a discussion about transplant-ineligible multiple myeloma (MM) by reacting to current treatment gaps that need to be addressed.

EP. 13: Management of Transplant-Ineligible Multiple Myeloma

ByONCOLOGY Staff

March 27th 2022

Experts provide their recommendations for navigating a large and continuously growing treatment landscape, selecting between regimens, and monitoring patients with transplant-ineligible multiple myeloma.

Management of Transplant-Ineligible Multiple Myeloma

EP. 1: Goals of Therapy for Transplant-Ineligible MM

EP. 2: Strategies to Monitor Multiple Myeloma

EP. 3: Frequency of Measuring Treatment Response in MM

EP. 4: MRD Testing in Multiple Myeloma

EP. 5: Managing Adequate/Inadequate Treatment Response in MM

EP. 6: Managing A Case of Newly-Diagnosed Transplant-Ineligible MM

EP. 7: Triplet Vs Doublet Therapy for Transplant-Ineligible MM

EP. 8: Maintenance Therapy for Transplant-Ineligible MM

EP. 9: Transplant-Ineligible MM: Treating to Progression

EP. 10: Transplant-Ineligible MM: Reinitiating Therapy

EP. 11: Counseling Patients With MM About Treatment Duration

EP. 12: Transplant-Ineligible MM: Navigating Treatment Challenges

EP. 13: Management of Transplant-Ineligible Multiple Myeloma

Trending on CancerNetwork

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

FDA Accepts sNDA for Taletrectinib in ROS1-Positive NSCLC

Achieving a “Functional Cure” With Multiple Myeloma Therapy